Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of eyelid colobomas associated with FREM1-related disorder (Manitoba oculotrichoanal syndrome).

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Orbital nocardiosis in immunocompetent patients: a case series and review of the literature.

Orbit (Amsterdam, Netherlands)·2026
Same author

Intersurgeon Variability in Proptosis Reduction After Orbital Decompression for Thyroid Eye Disease: A Multicenter Analysis.

Ophthalmic plastic and reconstructive surgery·2025
Same author

Mitomycin C in Non-endoscopic Endonasal Dacryocystorhinostomy: A Randomized Clinical Trial Involving 442 Cases.

American journal of ophthalmology·2025
Same author

Clinical characteristics and treatment outcomes of ocular myasthenia gravis at a tertiary eye care center in Eastern India.

Indian journal of ophthalmology·2025
Same author

The clinical spectrum of bulbar conjunctival rhinosporidiosis.

Indian journal of ophthalmology·2025

Related Experiment Video

Updated: May 21, 2026

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

Orbital radiotherapy for thyroid eye disease.

Peter J Dolman1, Suryasnata Rath

  • 1Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada. peterdolman@hotmail.com

Current Opinion in Ophthalmology
|June 26, 2012
PubMed
Summary
This summary is machine-generated.

Orbital radiotherapy for thyroid eye disease (TED) shows conflicting efficacy results. Recent reviews suggest it is most effective in early active phases, combined with glucocorticoids, and for specific complications like dysthyroid optic neuropathy.

More Related Videos

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

Related Experiment Videos

Last Updated: May 21, 2026

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Radiation Oncology

Background:

  • Orbital radiotherapy has a long history in treating thyroid eye disease (TED), often used with other therapies.
  • Despite extensive research, the efficacy of radiotherapy for TED remains debated, with inconsistent findings across studies.

Purpose of the Study:

  • To review recent systematic analyses on the use of orbital radiotherapy for thyroid eye disease (TED).
  • To synthesize current evidence regarding the effectiveness and optimal application of radiotherapy in managing TED.

Main Methods:

  • Systematic review of recent analyses and trials concerning radiotherapy for TED.
  • Analysis of differing conclusions based on disease heterogeneity, patient selection, and outcome measures.

Main Results:

  • Recent systematic reviews present divergent conclusions on radiotherapy's efficacy for TED.
  • Variations in study design, patient criteria, and outcome metrics (e.g., global indices vs. quality of life) contribute to conflicting results.

Conclusions:

  • Radiotherapy for TED is recommended primarily during the early active phase.
  • Optimal use involves combination therapy with glucocorticoids, particularly for dysthyroid optic neuropathy (DON), inflammatory changes, or motility issues.
  • Future research should explore radiotherapy's role in preventing/treating DON and compare combination therapy with glucocorticoid monotherapy.